Survivin drives renal cell carcinoma tumorigenesis via proliferative and metabolic adaptation
Disease Models & Mechanisms · 2026
DOI: 10.1242/dmm.052706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2026. Verfasst von Shivani Tuli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15213, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Survivin, Kidney Neoplasms, Carcinogenesis. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, University of Pittsburgh, NIH HHS.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) is a heterogeneous malignancy for which clear cell RCC (ccRCC) represents the most common and clinically aggressive subtype. Survivin (encoded by BIRC5), an inhibitor of apoptosis and key regulator of mitosis, is frequently overexpressed in RCC and associated with poor prognosis, yet its broader role in kidney cancer biology remains poorly defined. By analyzing transcriptomic data from The Cancer Genome Atlas-kidney renal clear cell carcinoma (TCGA-KIRC) cohort, we found that advanced-stage ccRCC exhibits widespread dysregulation of cell-cycle pathways, with 15,160 genes upregulated and 479 genes downregulated in stage IV compared to stage I tumors. To define survivin's functional contribution, we performed loss-of-function and pharmacologic inhibition studies in murine RENCA and human 786-O RCC cell lines. Survivin knockdown or treatment with the small-molecule inhibitor YM155 reduced proliferation, S-phase entry and cyclin D1 expression, and impaired collective (wound-healing), single-cell and transwell migration. Unexpectedly, survivin depletion increased mitochondrial content while lowering oxygen consumption, indicating accumulation of dysfunctional mitochondria. Together, these findings identify survivin as a node between cell-cycle progression and mitochondria in RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Department of Pathology and Anatomical Sciences, University at Buffalo, Buffalo, NY 14260, USA.
- Department of Biology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
ORCID-Profile: Shivani Tuli, Sarvesh Senguttavan, Yongho Bae, Dave Gau
Förderung
- NCATS NIH HHS
- University of Pittsburgh
- NIH HHS
- NHLBI NIH HHS
- NCI NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Tuli, S., Inserra, G., Murakami, Y., Vo, C., Senguttavan, S., Bae, Y., & Gau, D. (2026). Survivin drives renal cell carcinoma tumorigenesis via proliferative and metabolic adaptation. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052706
Vancouver
Tuli S, Inserra G, Murakami Y, Vo C, Senguttavan S, Bae Y, et al. Survivin drives renal cell carcinoma tumorigenesis via proliferative and metabolic adaptation. Disease Models & Mechanisms. 2026. doi:10.1242/dmm.052706
BibTeX
@article{Tuli2026,
author = {Tuli, Shivani and Inserra, Gabrielle and Murakami, Yamato and Vo, Cais and Senguttavan, Sarvesh and Bae, Yongho and Gau, Dave},
title = {Survivin drives renal cell carcinoma tumorigenesis via proliferative and metabolic adaptation},
journal = {Disease Models & Mechanisms},
year = {2026},
doi = {10.1242/dmm.052706}
}
EUVIMED